Gene Callais, MD
Family Medicine · Broussard, LANPI 1528315280
Payments from drug & device makers
Across 259 payments — averaging $15.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Novo Nordisk$438
- Lilly USA, LLC$436
- Amgen$369
- Boehringer Ingelheim$281
- Bayer$187
- plus $1K from 25 others
What the payments were for
- Food & beverage$4,136100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 74 | $1,145 |
| Novo Nordisk | 28 | $438 |
| Lilly USA, LLC | 31 | $436 |
| Amgen | 23 | $369 |
| Boehringer Ingelheim | 17 | $281 |
| Bayer | 12 | $187 |
| Novartis | 8 | $137 |
| AstraZeneca | 9 | $129 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 8 | $121 |
| GSK | 5 | $117 |
| Insulet Corporation | 5 | $105 |
| Abbott | 4 | $76 |
| Amarin Pharma, Inc. | 5 | $75 |
| Exact Sciences | 4 | $70 |
| Ardelyx, Inc. | 3 | $55 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $54 |
| Sanofi-aventis U.S. LLC | 3 | $49 |
| Johnson & Johnson | 2 | $37 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $35 |
| Tolmar, Inc. | 2 | $32 |
| Edwards Lifesciences | 1 | $32 |
| Dexcom, Inc. | 1 | $22 |
| Merck | 1 | $18 |
| Assertio Therapeutics, Inc. | 1 | $17 |
| Esperion Therapeutics, Inc. | 1 | $17 |
| Phathom Pharmaceuticals, Inc. | 1 | $15 |
| Boston Scientific | 1 | $15 |
| Sanofi Pasteur Inc. | 1 | $14 |
| Astellas Pharma US Inc | 1 | $14 |
| Genentech USA, Inc. | 1 | $13 |
| Pfizer | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VRAYLAR$125
How this compares
$4,136 in reported general payments places this provider in the 75th percentile of 1,469 family medicine providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 107 | $145,886 |
| OzempicSemaglutide | 65 | $67,701 |
| JardianceEmpagliflozin | 51 | $43,221 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 37 | $37,922 |
| EliquisApixaban | 40 | $37,897 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 39 | $35,112 |
| FarxigaDapagliflozin Propanediol | 22 | $24,549 |
| Repatha SureclickEvolocumab | 19 | $11,932 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 17 | $11,640 |
| EntrestoSacubitril/Valsartan | 15 | $11,333 |
| Trijardy XrEmpaglifloz/Linaglip/Metformin | 11 | $9,995 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 16 | $9,287 |
| Tresiba Flextouch U-200Insulin Degludec | 11 | $9,162 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 11 | $8,279 |
| LinzessLinaclotide | 12 | $6,198 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $436 | $145,886107 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Stiolto Respimat, Trijardy Xr | $281 | $102,778116 claims |
| Novo NordiskOzempic | $438 | $67,70165 claims |
| PfizerEliquis | $11 | $37,89740 claims |
| GSKTrelegy Ellipta | $117 | $35,11239 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $129 | $32,82833 claims |
| NovartisEntresto | $137 | $11,33315 claims |
| AbbVieLinzess, Synthroid | $1,145 | $7,34236 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,469 family medicine providers in Louisiana.
Other family medicine in Broussard
- Clinton GuilloryMonroe$18.5M
- Jason MorrisLake Charles$18M
- Michael SeepLake Charles$9.1M
- William NaboursLake Charles$3M
- Ramon VargasKenner$2.1M
- Stephen JonesNew Orleans$513K
- Joshua WhatleyLake Charles$366K
- Richard JeansonneMandeville$362K
- Kristen ThomasNew Orleans$361K
- Clint WilsonBossier City$208K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.